Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study

NCT02439320 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT02439320
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02439320 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2015
Completion date
August 31, 2016
Enrollment
2,231 (actual)
Sites
92

Conditions

As the registry lists them; a condition with its own page is linked.

acute migraine